Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Coates

Showing results (491-500 of 575) with videos related to

Pageof 58
Sort By:
Drug Safety|October 31, 2023
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic ArthritisBruce Strober, Laura C Coates, Mark G Lebwohl, et al.
The Journal of Rheumatology|February 16, 2022
Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working GroupAnna Antony, Richard Holland, Ashish J Mathew, et al.
BMJ Open|September 28, 2023
Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritisAlexander Ooms, Hussein Al-Mossawi, Louise Bennett, et al.
Annals of the Rheumatic Diseases|September 11, 2023
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL studyChristopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
The New Phytologist|June 7, 2014
AtMYB93 is a novel negative regulator of lateral root development in ArabidopsisDaniel J Gibbs, Ute Voß, Susan A Harding, et al.
Eclinicalmedicine|June 11, 2025
European advances in digital rheumatology: explainable insights and personalized digital health tools for psoriatic arthritisLeontios J Hadjileontiadis, Vasileios Charisis, Stelios Hadjidimitriou, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 8, 2021
Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal StudyLaura C Coates, Sreekumar G Pillai, Hasan Tahir, et al.
RMD Open|September 14, 2023
Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional studyYing Ying Leung, Lihi Eder, Ana-Maria Orbai, et al.
Rheumatology (Oxford, England)|May 31, 2022
Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDsLaura Tucker, Alexander Allen, David Chandler, et al.
Annals of the Rheumatic Diseases|June 19, 2025
Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414Christopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
Pageof 58

Showing results (491-500 of 575) with videos related to

Sort By:
Pageof 58
Drug Safety|October 31, 2023
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic ArthritisBruce Strober, Laura C Coates, Mark G Lebwohl, et al.
The Journal of Rheumatology|February 16, 2022
Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working GroupAnna Antony, Richard Holland, Ashish J Mathew, et al.
BMJ Open|September 28, 2023
Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritisAlexander Ooms, Hussein Al-Mossawi, Louise Bennett, et al.
Annals of the Rheumatic Diseases|September 11, 2023
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL studyChristopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
The New Phytologist|June 7, 2014
AtMYB93 is a novel negative regulator of lateral root development in ArabidopsisDaniel J Gibbs, Ute Voß, Susan A Harding, et al.
Eclinicalmedicine|June 11, 2025
European advances in digital rheumatology: explainable insights and personalized digital health tools for psoriatic arthritisLeontios J Hadjileontiadis, Vasileios Charisis, Stelios Hadjidimitriou, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 8, 2021
Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal StudyLaura C Coates, Sreekumar G Pillai, Hasan Tahir, et al.
RMD Open|September 14, 2023
Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional studyYing Ying Leung, Lihi Eder, Ana-Maria Orbai, et al.
Rheumatology (Oxford, England)|May 31, 2022
Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDsLaura Tucker, Alexander Allen, David Chandler, et al.
Annals of the Rheumatic Diseases|June 19, 2025
Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414Christopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
Pageof 58